CR9870A - DIHYDROGEN PHOSPHATE SALT OF A PROSTAGLANDIN D2 RECEIVER ANTAGONIST - Google Patents

DIHYDROGEN PHOSPHATE SALT OF A PROSTAGLANDIN D2 RECEIVER ANTAGONIST

Info

Publication number: CR9870A
Authority: CR; Costa Rica
Prior art keywords: prostaglandin; dihydrogen phosphate; phosphate salt; receiver antagonist; antagonist
Prior art date: 2005-10-13

Application number

CR9870A

Other languages

Spanish (es)

Inventor

Beverly Langevin

Edwuard Orton

Daniel Sherer

Original Assignee

Aventis Pharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-10-13

Filing date

2008-04-07

Publication date

2008-06-18

2008-04-07 Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc

2008-06-18 Publication of CR9870A publication Critical patent/CR9870A/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pulmonology (AREA)
Immunology (AREA)
Dermatology (AREA)
Ophthalmology & Optometry (AREA)
Rheumatology (AREA)
Vascular Medicine (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Anesthesiology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Urology & Nephrology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CR9870A 2005-10-13 2008-04-07 DIHYDROGEN PHOSPHATE SALT OF A PROSTAGLANDIN D2 RECEIVER ANTAGONIST CR9870A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US72629005P	2005-10-13	2005-10-13

Publications (1)

Publication Number	Publication Date
CR9870A true CR9870A (en)	2008-06-18

Family

ID=37963090

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CR9870A CR9870A (en)	2005-10-13	2008-04-07	DIHYDROGEN PHOSPHATE SALT OF A PROSTAGLANDIN D2 RECEIVER ANTAGONIST

Country Status (35)

Country	Link
US (1)	US7642249B2 (en)
EP (1)	EP1948620B1 (en)
JP (1)	JP2009511591A (en)
KR (1)	KR101365480B1 (en)
CN (1)	CN101287714B (en)
AR (1)	AR058085A1 (en)
AU (1)	AU2006304187B2 (en)
BR (1)	BRPI0617311A2 (en)
CA (1)	CA2625563C (en)
CR (1)	CR9870A (en)
DK (1)	DK1948620T3 (en)
DO (2)	DOP2006000223A (en)
EC (1)	ECSP088362A (en)
ES (1)	ES2409833T3 (en)
GT (1)	GT200600457A (en)
HN (1)	HN2008000603A (en)
HR (1)	HRP20130341T1 (en)
IL (1)	IL190673A (en)
MA (1)	MA30005B1 (en)
MY (1)	MY145648A (en)
NI (1)	NI200800116A (en)
NO (1)	NO20082072L (en)
NZ (1)	NZ567433A (en)
PE (1)	PE20070791A1 (en)
PL (1)	PL1948620T3 (en)
PT (1)	PT1948620E (en)
RS (1)	RS52799B (en)
RU (1)	RU2419614C2 (en)
SI (1)	SI1948620T1 (en)
TN (1)	TNSN08131A1 (en)
TW (1)	TW200728288A (en)
UA (1)	UA93062C2 (en)
UY (1)	UY29862A1 (en)
WO (1)	WO2007047378A2 (en)
ZA (1)	ZA200802586B (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HN2005000795A (en) *	2004-10-15	2010-08-19	Aventis Pharma Inc	PYRIMIDINS AS ANTAGONISTS OF PROSTAGLANDINA D2 RECEPTOR
AR060403A1 (en) *	2006-04-12	2008-06-11	Sanofi Aventis	AMINO COMPOUNDS- PYRIMIDINE 2.6- SUBSTITUTES -4- MONOSUSTITUTES AS ANTAGONISTS OF PROSTAGLANDINA D2 RECEIVER
MX2008015638A (en) *	2006-06-09	2009-01-09	Icos Corp	Substituted phenyl acetic acids as dp-2 antagonists.
JP2010532366A (en) *	2007-06-29	2010-10-07	サノフィ−アベンティス	A new method for preparing 2- (3- {6- [2- (2,4-dichlorophenyl) -ethylamino] -2-methoxypyrimidin-4-yl} -phenyl) -2-methylpropionic acid
WO2009099902A1 (en)	2008-02-01	2009-08-13	Amira Pharmaceuticals, Inc.	N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
WO2009108720A2 (en) *	2008-02-25	2009-09-03	Amira Pharmaceuticals, Inc.	Antagonists of prostaglandin d2 receptors
GB2463788B (en) *	2008-09-29	2010-12-15	Amira Pharmaceuticals Inc	Heteroaryl antagonists of prostaglandin D2 receptors
WO2010039977A2 (en)	2008-10-01	2010-04-08	Amira Pharmaceuticals, Inc.	Heteroaryl antagonists of prostaglandin d2 receptors
WO2010042652A2 (en)	2008-10-08	2010-04-15	Amira Pharmaceuticals, Inc.	Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors
WO2010045633A2 (en) *	2008-10-17	2010-04-22	National Jewish Health	Measurement and analysis of leukotrienes
TW201034675A (en) *	2008-12-18	2010-10-01	Sanofi Aventis	Method for treating macular degeneration
KR20120038544A (en)	2009-07-31	2012-04-23	판미라 파마슈티칼스, 엘엘씨	Ophthalmic pharmaceutical compositions of dp2 receptor antagonists
SG10201404662YA (en)	2009-08-05	2014-10-30	Panmira Pharmaceuticals Llc	Dp2 antagonist and uses thereof
EP2590640A1 (en)	2010-07-08	2013-05-15	Ramot at Tel-Aviv University Ltd	Use of fts and analogs to treat non-autoimmune-allergic and non-allergic inflammatory conditions
WO2012044561A2 (en) *	2010-09-30	2012-04-05	Merck Sharp & Dohme Corp.	2-alkoxy pyrimidine pde10 inhibitors
US9797903B2 (en)	2012-10-24	2017-10-24	Winthrop-University Hospital	Non-invasive biomarker to identify subject at risk of preterm delivery
US20180021302A1 (en)	2015-02-13	2018-01-25	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus
MY198769A (en)	2015-06-04	2023-09-25	Aurigene Oncology Ltd	Substituted heterocyclic derivatives as cdk inhibitors
US20200264188A1 (en)	2017-09-13	2020-08-20	Progenity, Inc.	Preeclampsia biomarkers and related systems and methods
EP4070113A4 (en)	2019-12-04	2023-12-20	Biora Therapeutics, Inc.	ASSESSMENT OF PREECLAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR TESTS

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4711888A (en) *	1985-07-24	1987-12-08	Pfizer Inc.	Hydroxy and alkoxy pyrimidines
DE60236322D1 (en) *	2001-12-07	2010-06-17	Vertex Pharma	PYRIMIDIN-BASED COMPOUNDS AS A GSK-3 HEMMER
EP1656350A2 (en) *	2003-07-09	2006-05-17	F.Hoffmann-La Roche Ag	Thiophenylaminoimidazolines as prostaglandin i2 antagonists
HN2005000795A (en) *	2004-10-15	2010-08-19	Aventis Pharma Inc	PYRIMIDINS AS ANTAGONISTS OF PROSTAGLANDINA D2 RECEPTOR

2006
- 2006-10-11 GT GT200600457A patent/GT200600457A/en unknown
- 2006-10-12 RU RU2008118491/04A patent/RU2419614C2/en not_active IP Right Cessation
- 2006-10-12 ES ES06825836T patent/ES2409833T3/en active Active
- 2006-10-12 NZ NZ567433A patent/NZ567433A/en not_active IP Right Cessation
- 2006-10-12 RS RS20130225A patent/RS52799B/en unknown
- 2006-10-12 PT PT68258367T patent/PT1948620E/en unknown
- 2006-10-12 HR HRP20130341TT patent/HRP20130341T1/en unknown
- 2006-10-12 UA UAA200806196A patent/UA93062C2/en unknown
- 2006-10-12 BR BRPI0617311-0A patent/BRPI0617311A2/en not_active IP Right Cessation
- 2006-10-12 KR KR1020087008805A patent/KR101365480B1/en not_active Expired - Fee Related
- 2006-10-12 CA CA2625563A patent/CA2625563C/en not_active Expired - Fee Related
- 2006-10-12 DK DK06825836.7T patent/DK1948620T3/en active
- 2006-10-12 AU AU2006304187A patent/AU2006304187B2/en not_active Ceased
- 2006-10-12 JP JP2008535672A patent/JP2009511591A/en not_active Abandoned
- 2006-10-12 SI SI200631572T patent/SI1948620T1/en unknown
- 2006-10-12 EP EP06825836A patent/EP1948620B1/en active Active
- 2006-10-12 MY MYPI20081085A patent/MY145648A/en unknown
- 2006-10-12 AR ARP060104475A patent/AR058085A1/en not_active Application Discontinuation
- 2006-10-12 PE PE2006001242A patent/PE20070791A1/en not_active Application Discontinuation
- 2006-10-12 WO PCT/US2006/039901 patent/WO2007047378A2/en not_active Ceased
- 2006-10-12 PL PL06825836T patent/PL1948620T3/en unknown
- 2006-10-12 CN CN2006800378860A patent/CN101287714B/en not_active Expired - Fee Related
- 2006-10-13 DO DO2006P000223A patent/DOP2006000223A/en unknown
- 2006-10-13 DO DO2006000220A patent/DOP2006000220A/en unknown
- 2006-10-13 TW TW095137635A patent/TW200728288A/en unknown
- 2006-10-13 UY UY29862A patent/UY29862A1/en unknown
2008
- 2008-03-19 TN TNP2008000131A patent/TNSN08131A1/en unknown
- 2008-03-20 ZA ZA200802586A patent/ZA200802586B/en unknown
- 2008-04-07 CR CR9870A patent/CR9870A/en not_active Application Discontinuation
- 2008-04-07 IL IL190673A patent/IL190673A/en not_active IP Right Cessation
- 2008-04-10 EC EC2008008362A patent/ECSP088362A/en unknown
- 2008-04-11 NI NI200800116A patent/NI200800116A/en unknown
- 2008-04-11 HN HN2008000603A patent/HN2008000603A/en unknown
- 2008-04-11 US US12/101,282 patent/US7642249B2/en not_active Expired - Fee Related
- 2008-05-02 MA MA30890A patent/MA30005B1/en unknown
- 2008-05-02 NO NO20082072A patent/NO20082072L/en not_active Application Discontinuation

Also Published As

Publication number	Publication date
CA2625563A1 (en)	2007-04-26
TW200728288A (en)	2007-08-01
EP1948620A2 (en)	2008-07-30
AU2006304187A1 (en)	2007-04-26
RU2008118491A (en)	2009-11-20
IL190673A0 (en)	2008-11-03
ZA200802586B (en)	2009-09-30
NI200800116A (en)	2011-12-15
ECSP088362A (en)	2008-05-30
WO2007047378A3 (en)	2007-08-02
JP2009511591A (en)	2009-03-19
AR058085A1 (en)	2008-01-23
HRP20130341T1 (en)	2013-05-31
MA30005B1 (en)	2008-12-01
UY29862A1 (en)	2007-05-31
HK1125133A1 (en)	2009-07-31
CN101287714B (en)	2011-04-06
RS52799B (en)	2013-10-31
DOP2006000223A (en)	2007-05-15
PL1948620T3 (en)	2013-08-30
DOP2006000220A (en)	2007-05-15
BRPI0617311A2 (en)	2011-07-19
AU2006304187B2 (en)	2011-04-28
US7642249B2 (en)	2010-01-05
WO2007047378A2 (en)	2007-04-26
KR101365480B1 (en)	2014-02-21
US20080194600A1 (en)	2008-08-14
MY145648A (en)	2012-03-15
ES2409833T8 (en)	2013-09-26
DK1948620T3 (en)	2013-06-24
UA93062C2 (en)	2011-01-10
ES2409833T3 (en)	2013-06-28
PT1948620E (en)	2013-05-06
PE20070791A1 (en)	2007-08-16
TNSN08131A1 (en)	2009-07-14
NO20082072L (en)	2008-05-02
GT200600457A (en)	2007-04-27
CN101287714A (en)	2008-10-15
NZ567433A (en)	2010-06-25
EP1948620B1 (en)	2013-03-20
IL190673A (en)	2011-12-29
RU2419614C2 (en)	2011-05-27
HN2008000603A (en)	2010-11-03
KR20080057275A (en)	2008-06-24
CA2625563C (en)	2011-04-19
SI1948620T1 (en)	2013-05-31

Publication	Publication Date	Title
CR9870A (en)	2008-06-18	DIHYDROGEN PHOSPHATE SALT OF A PROSTAGLANDIN D2 RECEIVER ANTAGONIST
CY1119218T1 (en)	2018-02-14	DIAHYDRODYPHYTHROPHALAZINONE SUSPENSIONS OF POLYMADENE PHOSPHOROSIS POLYMERASE (PARP)
EP1954290A4 (en)	2009-11-11	TRICYCLIC COMPOUNDS AS INHIBITORS OF KINASES
ATE373003T1 (en)	2007-09-15	PHOSPHORIC ACID SALT OF A DIPEPTIDYLPEPTIDASE IV INHIBITOR
IL213070A (en)	2016-09-29	Method for determining the efficacy of a pd-1 antagonist
BRPI1008829A2 (en)	2016-03-15	(r) -3- (4- (2- (2-Methyltetrazol-5-yl) pyridin-5-yl) -3-fluorophenyl) -5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate crystalline form
ATE449762T1 (en)	2009-12-15	CRYSTALLINE FORMS OF A BIPHENYL COMPOUND
IL224450B (en)	2018-01-31	Crystalline form of the pyrimido [1,6-a] isoquinoline-4-one compound
EP1926221A4 (en)	2011-12-28	SIGNAL TRANSMITTER
ATE479682T1 (en)	2010-09-15	CRYSTALLINE FORM OF A QUINOLINE-CARBOXAMIDE COMPOUND
DK1853686T3 (en)	2012-08-13	Lubricant concentrate containing a phosphate triester
EP2023727A4 (en)	2009-12-09	INHIBITORS OF THE PROSTAGLANDINE CARRIER
BRPI0718444A2 (en)	2013-11-19	Platelet ADP RECEIVER INHIBITORS
EP1972087A4 (en)	2012-08-01	SYMMETRIC TRUNKING OF A TRANSMITTER (TXOP)
GB2438811B (en)	2008-10-15	Acoustic generator for measuring distances by echoes
PL1723157T3 (en)	2008-04-30	Amorphous forms of risedronate monosodium
FI20075392A0 (en)	2007-05-30	Improving the sensitivity of the radio receiver
GB0525576D0 (en)	2006-01-25	Determining timing accuracy of a receiver
FI20050736A0 (en)	2005-07-08	Quality of a real-time service
DE602006003661D1 (en)	2008-12-24	AMPA RECEPTORS AMPLIFIER
ZA200801431B (en)	2009-07-29	Solid salt forms of a pyrrole substituted 2-indolinone
ITMI20061848A1 (en)	2008-03-28	PROCEDURE FOR THE PREPARATION OF PHENYLTETRAZOLIC COMPOUNDS
FI20040702A0 (en)	2004-05-21	A process for preparing a phosphate-containing suspension
BRPI0621575A2 (en)	2016-09-13	set of three-dimensional toy cylinder pipe connection parts
DE602005016615D1 (en)	2009-10-22	COMPENSATION OF PARASITIC COUPLING BETWEEN HF-NG

Legal Events

Date	Code	Title	Description
2013-08-29	FC	Refusal